Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'

Ann Oncol. 2019 Feb 1;30(2):344. doi: 10.1093/annonc/mdx823.
No abstract available

Publication types

  • Published Erratum